Agile Therapeutics, Inc.

The momentum for this stock is not very good. Agile Therapeutics, Inc. is not a good value stock. Agile Therapeutics, Inc. is not a good growth stock. Agile Therapeutics, Inc. is not very popular among insiders. Agile Therapeutics, Inc. is a mediocre stock to choose.

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercializa...

News

Agile Therapeutics, Inc. (NASDAQ:AGRX) Short Interest Update

Zolmax Agile Therapeutics, Inc. (NASDAQ:AGRX Get Free Report) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 361,300 shares, a...\n more…

Agile Therapeutics reports Q4 EPS ($1.51) vs (10c) last year

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Agile Therapeutics Q4 2023 Earnings Preview

SeekingAlpha.com: All News Agile Therapeutics is set to release its Q4 earnings results, with a consensus EPS estimate of -$0.92 and a revenue estimate of $4.07M (+1.8% YoY).\n more…

Why Agile Therapeutics (AGRX) Stock Is Down 60%

Benzinga Agile Therapeutics shares are trading lower by 61% during Tuesday's session. The company announced the suspension of its trading on the Nasdaq effective Tuesday.\n more…

Agile Therapeutics announces delisting from Nasdaq

Seeking Alpha - Healthcare Agile Therapeutics announces delisting from Nasdaq...\n more…